Sandoz appoints new Board representative to global AMR Industry Alliance
Oct 19, 2020
Dominic De Souza, global head of Anti-Infectives sustainability and AMR program, appointed to represent Sandoz on AMR Industry Alliance
Alliance brings together approximately 100 life science companies / associations in search of sustainable solutions to curb antimicrobial resistance (AMR)
Sandoz, as largest global provider of generic antibiotics, is committed to driving a pragmatic and balanced approach to tackling this growing global health threat
Holzkirchen, October 20, 2020 — Sandoz is pleased to announce the appointment of Dominic De Souza, global head of Anti-Infectives Sustainability and AMR Program, as its new representative to the Board of the AMR Industry Alliance.
The Alliance is a coalition of approximately 100 biotechnology, diagnostic, generic and research-based biopharmaceutical companies and trade associations, formed to drive and measure industry progress towards curbing antimicrobial resistance (AMR).
Dominic De Souza
Dominic De Souza assumes his new role with immediate effect. He replaces Harshika Sarbajna, the former global head of Anti-Infectives at Sandoz, who has taken up a new leadership position within the company. Sandoz would like to express its sincere thanks to Harshika for her committed efforts to drive the Sandoz AMR Program over the last few years.
Dominic De Souza said: “It gives me great professional and personal pride to join the Alliance Board, and I look forward to working with my colleagues across the industry to ensure a pragmatic and balanced approach to tackling this major global health threat, which is already responsible for the deaths of more than 700,000 people every year.”
“Antibiotics are the backbone of modern healthcare, treating previously incurable infectious diseases and drastically reducing the risks of millions of everyday medical procedures. However, AMR is a silent serial killer that, if allowed to continue developing, could lead to the end of modern medicine as we know it. My personal vision is to look back one day and tell my children that I was part of the global team who stopped that happening.”
Dominic De Souza joined Sandoz in 2006 and has held progressive roles ranging from product development via production management to commercial. He is an Austrian citizen and holds a doctorate in Organic Chemistry from the University of Technology in Graz. He is based in Kundl, Austria, the global production hub of the Sandoz Anti-Infectives business.
Sandoz, the #1 global supplier of generic antibiotics, recently announced plans for a joint investment of more than EUR 150 million in Kundl, to help secure the future of antibiotics manufacturing in Europe.
Disclaimer This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.
About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical need. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2019 sales of USD 9.7 billion.